Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 731-740

  Gulati, Nicholas ^a   Karsy, Michael ^a   Albert, Ladislau ^a   Murali, Raj ^a   Jhanwar Uniyal, Meena ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

AKT; Glioblastoma multiforme; Mammalian target of Rapamycin; Rapamycin insensitive companion of mTOR; Rapamycin sensitive adapter protein of mTOR

Indexed keywords

FIBRONECTIN; GENE PRODUCT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR C; PROTEIN KINASE B; RAPAMYCIN; RAPTOR PROTEIN; RICTOR PROTEIN; S6 KINASE; SERINE; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVE TRANSPORT, CELL NUCLEUS; ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMONES; ENZYME ACTIVATION; FIBRONECTINS; GLIOBLASTOMA; HUMANS; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; THREONINE; TIME FACTORS;

EID: 70449457461     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000386     Document Type: Article

References (45)

1. Kallio M, Sankila R, Jaaskelainen J, Karjalainen S and Hakulinen T: A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984. Cancer 68: 1394-1400, 1991.
2. Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma: Am J Pathol 170: 1445-1453, 1991.
3. Wiedemeyer R, Brennan C, Heffernan TP, Xiao Y, Mahoney J, Protopopov A, Zheng H, Bignell G, Furnari F, Cavenee WK, Hahn WC, Ichimura K, Collins VP, Chu GC, Stratton MR, Ligon KL, Futreal PA and Chin L: Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 13: 355-364, 2008.
4. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021, 2004. (Pubitemid 39331011)
5. Holland EC, Hively WP, DePinho RA and Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675-3685, 1998.
6. Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med 353: 811-822, 2005.
7. Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L, La Torre G, Sabatino G, Maira G, Jhanwar-Uniyal M and Sica G: Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 13: 6970-6977, 2007. (Pubitemid 350276877)
8. Nutt C and Louis DN: Cancer of Nervous System. 2nd edition. McGraw-Hill, New York, 2005.
9. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M and Holland EC: mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7: 356-368, 2005. (Pubitemid 40664225)
10. Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA, Geschwind DH, Liu X, Kornblum HI and Wu H: PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 103: 111-116, 2006. (Pubitemid 43076113)
11. Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18: 1926-1945, 2004.
12. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006. (Pubitemid 43357943)
13. Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2: 120-129, 2001.
14. Jacinto E and Hall MN: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4: 117-126, 2003. (Pubitemid 36172695)
15. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
16. Sabatini DM: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734, 2006.
17. Easton JB, Kurmasheva RT and Houghton PJ: IRS-1: auditing the effectiveness of mTOR inhibitors. Cancer Cell 9: 153-155, 2006.
18. Volarevic S and Thomas G: Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 65: 101-127, 2001.
19. Reiling JH and Sabatini DM: Stress and mTORture signaling. Oncogene 25: 6373-6383, 2006.
20. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE and Pagano M: Science 314: 467-471, 2006.
21. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP and Lamb RF: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223, 2004. (Pubitemid 38988774)
22. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C and Bouscary D: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382, 2008.
23. Rajan P and McKay RD: Multiple routes to astrocytic differentiation in the CNS. J Neurosci 18: 3620-3629, 1998. (Pubitemid 28225670)
24. Yokogami K, Wakisaka S, Avruch J and Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10: 47-50, 2000. (Pubitemid 30057415)
25. De l, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, DePinho RA and Bonni A: Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22: 449-462, 2008.
26. Riemenschneider MJ, Betensky RA, Pasedag SM and Louis DN: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66: 5618-5623, 2006.
27. Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688, 2006. (Pubitemid 44151605)
28. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M and Walsh DJ: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304, 2005. (Pubitemid 46206983)
29. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J and Prados MD: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361, 2005. (Pubitemid 40980358)
30. Fan QW and Weiss WA: Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 5: 2301-2305, 2006.
31. Berens ME and Beaudry C: Radial monolayer cell migration assay. Methods Mol Med 88: 219-224, 2004.
32. Shah OJ, Wang Z and Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656, 2004. (Pubitemid 39239362)
33. Zeng M and Zhou JN: Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. Cell Signal 20: 659-665, 2008.
34. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D and Baselga J: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610, 2008.
35. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X and Holland EC: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901, 2003. (Pubitemid 37352782)
36. Manning BD, Tee AR, Logsdon MN, Blenis J and Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162, 2002. (Pubitemid 34876569)
37. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
38. Kubica N, Crispino JL, Gallagher JW, Kimball SR and Jefferson LS: Activation of the mammalian target of rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bvarepsilon mRNA translation and protein synthesis. Int J Biochem Cell Biol 40: 2522-2533, 2008.
39. Burnett PE, Blackshaw S, Lai MM, Qureshi IA, Burnett AF, Sabatini DM and Snyder SH: Neurabin is a synaptic protein linking p70 S6 kinase and the neuronal cytoskeleton. Proc Natl Acad Sci USA 95: 8351-8356, 1998. (Pubitemid 28326116)
40. Peterson RT, Desai BN, Hardwick JS and Schreiber SL: Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 96: 4438-4442, 1999. (Pubitemid 29190354)
41. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005. (Pubitemid 41215743)
42. Liu L, Chen L, Chung J and Huang S: Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 27: 4998-5010, 2008.
43. Holt RU, Fagerli UM, Baykov V, Ro TB, Hov H, Waage A, Sundan A and Borset M: Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica 93: 619-622, 2008.
44. Bachmann RA, Kim JH, Wu AL, Park IH and Chen J: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem 281: 7357-7363, 2006.
45. Salomoni P and Pandolfi PP: The role of PML in tumor suppression. Cell 108: 165-170, 2002.